Physician profile
Robert C Candipan
NPI 1457375529
$32,152.73
in general payments reported to CMS, 2019-2025
41 companies · $11K in 2025
The $11K reported for 2025 was more than what 89% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $1,562 · 2021: $1,371 · 2022: $2,036 · 2023: $1,158 · 2024: $2,282 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $11K · Food and Beverage: $3,358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $10,830.35 |
| Food and Beverage | $3,358.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $12,810.56 | 2021-2025 | Abre, Symplicity G3, Hawkone |
| Medtronic Vascular, INC. | $11,536.38 | 2019-2020 | |
| Cardiovascular Systems INC. | $2,034.18 | 2019-2020 | |
| Shockwave Medical, INC | $806.35 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $587.80 | 2021-2024 | Optimizer, Optimizer |
| Merck Sharp & Dohme LLC | $544.54 | 2021-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $527.88 | 2021-2025 | |
| Abbott Laboratories | $461.33 | 2019-2023 | Mitraclip, Aptivue |
| Boston Scientific Corporation | $322.53 | 2019-2025 | General - Therapies |
| Janssen Pharmaceuticals, INC | $278.59 | 2019-2024 | Xarelto |
| Amgen INC. | $267.54 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $202.65 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $177.88 | 2019-2025 | Lifevest |
| Angiodynamics, INC. | $159.66 | 2020-2022 | |
| Novo Nordisk INC | $146.09 | 2022-2025 | Wegovy, Ozempic |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Candipan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.